中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共3条，第1-3条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) 期刊论文
CANCER BIOLOGY & THERAPY, 2019, 卷号: 20, 期号: 6, 页码: 877-885
作者:  Wu, Jiaxin;  Wang, Aoli;  Li, Xixiang;  Chen, Cheng;  Qi, Ziping;  Hu, Chen;  Wang, Wenliang;  Wu, Hong;  Huang, Tao;  Zhao, Ming;  Wang, Wenchao;  Hu, Zhenquan;  Liu, Qingwang;  Wang, Beilei;  Wang, Li;  Li, Lili;  Ge, Jian;  Ren, Tao;  Xia, Ruixiang;  Liu, Jing
收藏  |  浏览/下载：58/0  |  提交时间：2019/11/27
BCR-ABL  PDGFR  chronic myeloid leukemia  kinase inhibitor  
Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino) cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl) tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 158, 页码: 896-916
作者:  Wang, Beilei;  Wu, Jiaxin;  Wu, Yun;  Chen, Cheng;  Zou, Fengming;  Wang, Aoli;  Wu, Hong;  Hu, Zhenquan;  Jiang, Zongru;  Liu, Qingwang;  Wang, Wei;  Zhang, Yicong;  Liu, Feiyang;  Zhao, Ming;  Hu, Jie;  Huang, Tao;  Ge, Juan;  Wang, Li;  Ren, Tao;  Wang, Yuxin;  Liu, Jing;  Liu, Qingsong
收藏  |  浏览/下载：29/0  |  提交时间：2019/12/25
CDK9  Kinase inhibitor  Structure-activity relationship  Leukemia  
Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3K delta) inhibitor 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 156, 页码: 831-846
作者:  Liang, Xiaofei;  Li, Feng;  Chen, Cheng;  Jiang, Zongru;  Wang, Aoli;  Liu, Xiaochuan;  Ge, Juan;  Hu, Zhenquan;  Yu, Kailin;  Wang, Wenliang;  Zou, Fengming;  Liu, Qingwang;  Wang, Beilei;  Wang, Li;  Zhang, Shanchun;  Wang, Yuxin;  Liu, Qingsong;  Liu, Jing
收藏  |  浏览/下载：58/0  |  提交时间：2019/12/10
PI3K delta  Kinase inhibitor  Acute myeloid leukemia  Structure-activity relationship